Matthew Ronsheim
Corporate Officer/Principal bij ENTASIS THERAPEUTICS HOLDINGS INC.
Vermogen: 639 653 $ op 31-05-2024
Profiel
Matthew Ronsheim is currently the Chief Pharmaceutical Sciences Officer at Entasis Therapeutics Holdings, Inc. Prior to this, he was the Executive Director & Head-Chemistry Manufacturing at Enanta Pharmaceuticals, Inc. from 2016 to 2019.
He received his undergraduate degree from Southern Connecticut State University and his doctorate from the University of New Hampshire.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
INNOVIVA, INC.
0.06% | 20-05-2024 | 40 510 ( 0.06% ) | 639 653 $ | 31-05-2024 |
Actieve functies van Matthew Ronsheim
| Bedrijven | Functie | Begin |
|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01-09-2020 |
Eerdere bekende functies van Matthew Ronsheim
| Bedrijven | Functie | Einde |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 01-08-2019 |
Opleiding van Matthew Ronsheim
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
